A similar, once daily, extended release formulation of dapagliflozin with metformin was recently approved in the us. This review summarizes current evidence from clinical trials assessing the clinical efficacy and safety of dapagliflozin, and presents data regarding its cost-effectiveness. Sodiumglucose cotransporter 2 (sglt2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action.
Farxiga is a registered trademark and az&me is a trademark of the astrazeneca group of companies. Tell your doctor if you have any signs or symptoms of uti including a burning feeling when passing urine, a need to urinate often, the need to urinate right away, pain in the lower part of your stomach (pelvis), or blood in the urine with or without fever, back pain, nausea, or vomiting can occur if you take farxiga with another medicine that can cause low blood sugar, such as sulfonylureas or insulin. Finally, when used as third-line therapy as adjunct to metformin and sitagliptin, dapagliflozin resulted in significant weight loss compared with placebo (2.
Almost two-thirds of the observed body weight reduction with dapagliflozin was attributed to loss of fat mass, which is probably related to the caloric loss induced by glucosuria a recent meta-analysis investigated the effects of sglt2 inhibitors on blood pressure. It can also be used as an adjunct to other glucose-lowering agents including insulin for patients with inadequate glycaemic control. Prevalence of t2dm is expected to increase in the following years with projections suggesting that 69 million europeans will be affected by 2035 (10.
Nevertheless, the approved summary of product characteristics in europe suggests that dapagliflozin is initiated at a daily dose of 10 mg. Incidence of hypoglycaemia was approximately 10-fold less with dapagliflozin relative to glipizide. The pathophysiology of t2dm is characterized by insulin resistance and progressive loss of -cell function.
The secret to managing type 2 diabetes is to take small steps and your first step is to sign up now. There were too few cases of bladder cancer to know if bladder cancer was related to farxiga. Dapagliflozin is a member of the sglt2 inhibitors class that has received marketing authorization in europe and the us.
Based on the latest data submitted by the drug sponsors to the us food and drug administration, 10 cases (0. A higher incidence of breast cancer was noted in patients treated with dapagliflozin (nine women, n 5501 as opposed to one patient in the control group, n 3148). . These effects are attributed to osmotic diuresis associated with use of dapagliflozin and were corroborated in 2 trials using 24-hour ambulatory blood pressure monitoring. Important safety information, approved uses, prescribing information, medication guide farxiga is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Your e-mail address and that of your recipient will be used for transmission of this e-mail only and will not be stored or used for any other purpose. A higher incidence of breast cancer was noted in patients treated with dapagliflozin (nine women, n 5501 as opposed to one patient in the control group, n 3148). Similar results were observed for use of dapagliflozin as add-on to pioglitazone for 48 weeks (2. Talk to your healthcare provider if you experience redness, itching, or swelling of the penis rash of the penis foul smelling discharge from the penis or pain in the skin around penis. Follow your healthcare providers instructions for treating low blood sugar in women who take farxiga.
Current guidelines advocate the use of metformin as first-line treatment, while other hypoglycaemic drugs are indicated only when metformin is considered inappropriate due to intolerance. Symptoms of low blood sugar include shaking, sweating, fast heartbeat, dizziness, hunger, headache, and irritability. For patients already treated with background metformin use of dapagliflozin, reduced hba compared with glipizide (mean difference 0. Type 2 diabetes mellitus (t2dm) has reached epidemic proportions affecting 56 million people in europe, accounting for 8. Treatment is based on the use of therapeutic agents that address these problems.
Dapagliflozin is indicated along with diet and exercise as monotherapy for patients with t2dm who are intolerant to metformin or for whom metformin is contraindicated. Moreover, treatment with dapagliflozin does not increase risk for hypoglycaemia, but is associated with increased incidence of mild to moderate urinary and genital tract infections. As monotherapy, dapagliflozin was equally effective with metformin in reducing body weight (1. Based on the latest data submitted by the drug sponsors to the us food and drug administration, 10 cases (0. Moreover, in patients treated with basal insulin at a dose of at least 30 international unit (iu)day and up to two other antidiabetic agents, addition of dapagliflozin 10 mg effectively reduced hba compared with placebo over 2 years of treatment (0. These effects are attributed to osmotic diuresis associated with use of dapagliflozin and were corroborated in 2 trials using 24-hour ambulatory blood pressure monitoring. Farxiga should not be used to treat people with type 1 diabetes or diabetic ketoacidosis (increased ketones in your blood or urine). Similar findings were reported in a meta-analysis of 14 trials (or 0. Hospitalization for unstable angina or heart failure, as well as all-cause mortality, will also be investigated. Clinical research and evidence-based medicine unit, second medical department, aristotle university thessaloniki, thessaloniki, greece second medical department, aristotle university thessaloniki, thessaloniki, greece associate professor of medicine, clinical research and evidence-based medicine unit, second medical department, aristotle university thessaloniki, hippokratio general hospital, 49 konstantinoupoleos street, 54642, thessaloniki, greece clinical research and evidence-based medicine unit, second medical department, aristotle university thessaloniki, thessaloniki, greece sodium-glucose cotransporter 2 (sglt2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action.Mar 28, 2018 ... FORXIGA® is a registered trademark of AstraZeneca AB, used under license by AstraZeneca. Canada .... tablet / 5 mg, 10 mg. Lactose ..... Infections were more frequently reported in females (9.6% [56/581] and 7.7% [46/598].